49 results
6-K
EX-99.1
BLU
Bellus Health Inc
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
in the regulatory environment in the jurisdictions in which BELLUS Health does business, supply chain impacts, stock market volatility, fluctuations in costs
6-K
EX-99.1
BLU
Bellus Health Inc
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
or at all, changes in the regulatory environment in the jurisdictions in which BELLUS Health does business, supply chain impacts, stock market volatility
6-K
EX-99.1
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
, including impact to the initiation and completion of clinical trials in a timely manner or at all, changes in the regulatory environment, supply chain impacts
6-K
EX-99.1
BLU
Bellus Health Inc
5 Jul 22
BELLUS Health to Participate in the William Blair Biotech Focus Conference
7:00am
BELLUS Health does business, supply chain impacts, stock market volatility, fluctuations in costs, changes to the competitive environment due
6-K
EX-99.1
BLU
Bellus Health Inc
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
manner or at all, changes in the regulatory environment in the jurisdictions in which BELLUS Health does business, supply chain impacts, stock market
6-K
EX-99.1
10imgg67h1b00u
1 Jun 22
BELLUS Health to Participate in the Jefferies Healthcare Conference
7:00am
6-K
EX-99.1
kyd0htn qb
22 Aug 22
Bellus Health Inc. 6-K
7:01am
6-K
EX-99.1
xv2sdy
1 Nov 21
Bellus Health Inc. 6-K
7:00am
6-K
EX-99.2
kj49sap7c8f xqn
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
hdi v10qn1sda
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.1
ynenx
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.2
6uq9aa
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
cqti1k
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
6-K
EX-99.2
8zcs q6b3l4zbyp
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.2
qf4x t25f9ps8
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
wej2 pevhr43822
23 Feb 22
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
4:01pm
6-K
EX-99.1
cyq66jlg4ymac
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:00am
6-K
EX-99.2
29ailaq s3gvxh8jn3
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
6-K
EX-99.1
zghv2vd
10 Aug 22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
4:31pm
6-K
EX-99.1
v1s3tzff0w
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm